Surv-Biopharma’s Oncolytic Virus Surv.m-CRA-1 Receives Orphan Drug Designation for Primary Malignant Bone Tumor
Key facts
- Surv-Biopharma’s Oncolytic Virus Surv.m-CRA-1 Receives Orphan Drug Designation for Primary Malignant Bone Tumor
- 鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
- Source: PR Times
- Date: May 12, 2026
Direct answer
鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
- Citation
- Surv-Biopharma’s Oncolytic Virus Surv.m-CRA-1 Receives Orphan Drug Designation for Primary Malignant Bone Tumor (May 12, 2026), PR Times
- Source
- PR Times
- Date
- May 12, 2026
鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 04:32
- 🔍 Collected: May 11, 2026 at 20:02
- 🤖 AI Analyzed: May 16, 2026 at 02:54 (102h 52m after Collected)
Surv-Biopharma Inc., a biotech startup from Kagoshima University, announced that its oncolytic adenovirus "Surv.m-CRA-1" has been designated as an "Orphan Regenerative Medicine Product" by the Ministry of Health, Labour and Welfare of Japan. The therapy utilizes a survivin promoter to selectively destroy cancer cells while sparing healthy tissue. Currently in Phase III physician-led clinical trials, Surv.m-CRA-1 targets primary malignant bone tumors, a rare and difficult-to-treat cancer with high unmet medical needs. This designation provides incentives such as subsidies and priority review.
FAQ
What are the key facts in this article?
鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
What is the direct answer?
鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
What is the source and date?
PR Times: https://prtimes.jp/main/html/rd/p/000000012.000165403.html | May 12, 2026